Cellectis S.A. (NASDAQ:CLLS) Stock Has Average Target Price of $5.46

Cellectis S.A. (NASDAQ:CLLS) has been assigned an average recommendation of “Hold” from the seven research firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $5.46.

Several equities research analysts have issued reports on CLLS shares. Robert W. Baird cut their price objective on shares of Cellectis from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Tuesday, September 15th. Barclays downgraded Cellectis from an “overweight” rating to an “underweight” rating and dropped their target price for the stock from $9.00 to $1.30 in a report on Wednesday, September 16th. Citizens Jmp restated a “market perform” rating on shares of Cellectis in a research note on Tuesday, September 15th. Weiss Ratings upgraded shares of Cellectis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Finally, Wells Fargo & Company lowered their price target on shares of Cellectis from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday, September 15th.

Cellectis Stock Performance

CLLS stock opened at $1.43 on Wednesday. The company has a debt-to-equity ratio of 1.61, a current ratio of 1.37 and a quick ratio of 1.37. The company has a fifty day moving average price of $2.61 and a two-hundred day moving average price of $3.12. Cellectis has a one year low of $1.25 and a one year high of $5.48. The stock has a market cap of $143.49 million, a price-to-earnings ratio of -2.20 and a beta of 3.00.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04. The firm had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.

Institutional Investors Weigh In On Cellectis

A hedge fund recently bought a new stake in Cellectis stock. Lido Advisors LLC purchased a new position in shares of Cellectis S.A. (NASDAQ:CLLS) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

About Cellectis

Cellectis is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic cell therapies for the treatment of cancer. The company uses its TALEN gene-editing technology to modify immune cells, including T cells, with the goal of creating “off-the-shelf” therapies that can be manufactured in advance and administered to multiple patients.

Cellectis’ development programs include UCART, or Universal Chimeric Antigen Receptor T-cell, therapies designed to target specific cancer antigens.